APR 23, 2020 7:54 AM PDT

Doctors, watch out for unexpected side effects in small clinical trials

Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpected side effects suggests new research with was published recently in the journal Frontiers in Oncology. Led by medical oncologist, Tejas Patil, MD, and trauma surgeon, Lisa Ferrigno, MD, MPH, FACS, the published case series highlights an emerging trend in oncological clinical trials and warns physicians to be extra alert.

"You have drugs getting out onto the market with fewer numbers involved in terms of testing, so the lay of the land with adverse effects might not be completely hashed out. There are not many people who have taken the drug," explains Ferrigno.

When Patil and Ferrigno first noticed an unanticipated side effect occurring in their patients with lung cancer in a University of Colorado Cancer Center clinical trial, they were surprised. The trial was with the drug osimertinib (Tagrisso), which has shown success as a genetically targeted anti-cancer drug. But what the physicians noticed in their patients was a rare twist in the right side of their colons, a condition known as cecal volvulus

"When your first patient has it, you just think it's a one-off. Then you see it again and see it again, and once you get to your third patient, you start to think it's a pattern. We noticed all these patients were getting the same dose of osimertinib, and it prompted me to think it's not one-off, but a dose-exposure relationship," says Patil.

Interestingly, the doctors noticed that only patients treated with 160mg doses who developed this possible side effect, while those treated with 80mg doses of osimertinib did not.

"Studies show 160mg is a pretty reasonable dose for osimertinib in many cases, so we expect to see this dose used even more, maybe leading to more of this kind of side effect. That's why it's important to start noticing these observations now," Patil says.

Photo: Pixabay

Their observations about this case series serve as an alarm signal for other clinical trials that test drugs on small populations of patients. As Eureka Alert reports, “Smaller studies reduce the likelihood of seeing rare side effects; and so it may fall on clinicians using these drugs after FDA approval to notice medication side effects that went undetected during clinical trials.”

Sources: Frontiers in Oncology, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 15, 2021
Cancer
Red seaweed consumption is associated with a low risk of colon cancer - but why?
JUN 15, 2021
Red seaweed consumption is associated with a low risk of colon cancer - but why?
New research published in Marine Drugs explains why diets high in red seaweed are associated with a low risk of col ...
AUG 19, 2021
Immunology
Immune Enzyme Kills Viruses but Makes Tumors Stronger
AUG 19, 2021
Immune Enzyme Kills Viruses but Makes Tumors Stronger
Robert Louis Stevenson’s 1886 novel Strange Case of Dr. Jekyll and Mr. Hyde describes a man who is a kind, respect ...
AUG 18, 2021
Cell & Molecular Biology
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
AUG 18, 2021
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
For many years, researchers have studied how an enzyme called APOBEC3 can help protect the body from pathogenic viruses, ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
SEP 02, 2021
Immunology
Hobit Activates Cancer-Killing Immune Cells
SEP 02, 2021
Hobit Activates Cancer-Killing Immune Cells
Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. Thes ...
Loading Comments...